GSK (GSK) adds 45,273 ordinary shares to LSE Main Market listing
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.
Positive
- None.
Negative
- None.
Key Figures
New shares admitted: 45,273 shares
Total shares admitted: 4,316,221,551 shares
Nominal value per share: 31¼ pence
+1 more
4 metrics
New shares admitted
45,273 shares
Further ordinary shares admitted to trading
Total shares admitted
4,316,221,551 shares
Total GSK ordinary shares after admission
Nominal value per share
31¼ pence
Nominal value of each ordinary share
Notification date range
27 March 2026 - 22 May 2026
Period covered by the admission notification
Key Terms
block listing admissions, Share Save Plan 2022, fungible, Form 20-F, +1 more
5 terms
block listing admissions regulatory
"admitted to trading under existing block listing admissions of Ordinary Shares"
fungible financial
"Fungibility | Fully fungible with existing Ordinary Shares"
Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover of Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
foreign private issuer regulatory
"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
FAQ
What did GSK (GSK) disclose in this May 2026 Form 6-K?
GSK disclosed that 45,273 additional ordinary shares have been admitted to trading on the London Stock Exchange Main Market. These shares arise under existing block listings linked to the GlaxoSmithKline plc Share Save Plan 2022, increasing total admitted shares to 4,316,221,551.